Stockscreener 앱 받기
2.17
1.88%
0.04
시장 영업 전:
2.18
0.01
+0.46%
전일 마감가:
$2.13
열려 있는:
$2.14
하루 거래량:
4.86M
Relative Volume:
1.08
시가총액:
$437.52M
수익:
$116.33M
순이익/손실:
$-209.25M
주가수익비율:
-1.0236
EPS:
-2.12
순현금흐름:
$-135.49M
1주 성능:
+5.85%
1개월 성능:
+77.87%
6개월 성능:
+19.23%
1년 성능:
+26.90%
1일 변동 폭
$2.13
$2.20
1주일 범위
$2.00
$2.20
52주 변동 폭
$0.6925
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
명칭
Esperion Therapeutics Inc
전화
734-887-3903
주소
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
ESPR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
2.17 | 423.41M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
156.62 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.52 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.46 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
312.23 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-18 | 개시 | Goldman | Neutral |
| 2024-12-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-06-20 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-08-01 | 업그레이드 | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | 업그레이드 | BofA Securities | Underperform → Buy |
| 2023-03-16 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-03-16 | 다운그레이드 | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | 재개 | BofA Securities | Neutral |
| 2023-02-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-03-10 | 개시 | H.C. Wainwright | Buy |
| 2021-10-19 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-02-12 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-02-09 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-01-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-11-10 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | 재개 | JP Morgan | Underweight |
| 2020-08-11 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | 재개 | BofA/Merrill | Buy |
| 2020-03-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-02-24 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-09-16 | 업그레이드 | Goldman | Sell → Neutral |
| 2019-05-29 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-05-06 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | 업그레이드 | Goldman | Sell → Neutral |
| 2019-03-13 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2019-01-07 | 재확인 | Needham | Strong Buy |
| 2018-12-13 | 개시 | Goldman | Sell |
| 2018-10-29 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | 개시 | BTIG Research | Buy |
| 2018-08-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2018-07-11 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-05-02 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
모두보기
Esperion Therapeutics Inc 주식(ESPR)의 최신 뉴스
Esperion rises after revenue beat, Q1 profitability expectation - MSN
Three Analyst Favorites with Potential for Further Gains: SkyWater Technology, Emergent BioSolutions, and More - AInvest
Detecting support and resistance levels for Esperion Therapeutics Inc.Stock Surge & Safe Entry Momentum Tips - Newser
Chart based analysis of Esperion Therapeutics Inc. trendsWeekly Market Report & AI Forecasted Entry/Exit Points - Newser
Is Esperion Therapeutics Inc. still worth holding after the dip2025 Short Interest & Community Consensus Picks - Newser
Esperion Therapeutics soars amid vague takeover speculation - MSN
Best data tools to analyze Esperion Therapeutics Inc. stockTrade Risk Report & Risk Controlled Daily Plans - Newser
Esperion Therapeutics Inc. stock outlook for YEARPortfolio Update Report & Stepwise Entry/Exit Trade Alerts - Newser
Is Esperion Therapeutics Inc. a Top Dividend Stock to Watch in 2025Market Movers & AI Based Trade Execution Alerts - Newser
Applying sector rotation models to Esperion Therapeutics Inc.Market Growth Summary & Free Low Drawdown Momentum Trade Ideas - Newser
Esperion Therapeutics (NASDAQ:ESPR) Upgraded at Wall Street Zen - Defense World
Pattern recognition hints at Esperion Therapeutics Inc. upsideStock Surge & Risk Adjusted Buy/Sell Alerts - Newser
What MACD signals say about Esperion Therapeutics Inc.July 2025 PostEarnings & Step-by-Step Swing Trade Plans - Newser
Real time scanner hits for Esperion Therapeutics Inc. explainedJuly 2025 Earnings & Smart Money Movement Alerts - Newser
Will Esperion Therapeutics Inc. price bounce be sustainableCEO Change & Daily Market Momentum Tracking - Newser
What the charts say about Esperion Therapeutics Inc. today2025 Price Targets & Long Hold Capital Preservation Tips - Newser
Is Esperion Therapeutics Inc. stock poised for growth2025 EndofYear Setup & Stock Portfolio Risk Control - Newser
Backtesting results for Esperion Therapeutics Inc. trading strategiesWeekly Gains Summary & Breakout Confirmation Trade Signals - Newser
Assessing Madrigal Pharmaceuticals' Long-Term Market Potential in the LDL-C Lowering Therapy Sector Amid Competitive Dynamics - AInvest
Is a relief rally coming for Esperion Therapeutics Inc. holdersDollar Strength & Free High Accuracy Swing Entry Alerts - Newser
Signal strength of Esperion Therapeutics Inc. stock in tech scannersJuly 2025 Update & Short-Term Trading Opportunity Alerts - Newser
Can Esperion Therapeutics Inc. Regain Momentum After BreakdownJuly 2025 Rallies & Safe Entry Trade Reports - beatles.ru
What earnings revisions data tells us about Esperion Therapeutics Inc.Quarterly Profit Review & Real-Time Buy Signal Notifications - Newser
Wall Street Zen Upgrades Esperion Therapeutics (NASDAQ:ESPR) to "Hold" - MarketBeat
Esperion Delays Q2 2025 Financial Report Filing - MSN
Competitive Positioning of Esperion Therapeutics Inc.: Is It Leading or LaggingFree Intraday Trend Analysis for Fast Gains - Newser
Published on: 2025-08-10 18:32:11 - beatles.ru
FY2025 EPS Estimates for ESPR Boosted by Cantor Fitzgerald - Defense World
Esperion Therapeutics Inc. At Decision Level — Rebound or ResistanceExpert Verified Stock Trade Ideas Backed by Data - beatles.ru
ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises - MSN
Esperion Therapeutics (NASDAQ:ESPR) Upgraded to Hold at Wall Street Zen - Defense World
HC Wainwright Issues Positive Outlook for ESPR Earnings - Defense World
Published on: 2025-08-08 10:01:24 - beatles.ru
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) for New Employees - AInvest
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Esperion Grants 73,500 RSUs with 4-Year Vesting Schedule to Attract Top Talent - Stock Titan
Esperion Therapeutics’ Earnings Call Highlights Growth - The Globe and Mail
Esperion (ESPR) Q2 Revenue Jumps 12% - AOL.com
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates - MSN
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q2 2025 Earnings Call Transcript - Insider Monkey
Esperion expects sustainable profitability in Q1 2026 as double-digit growth continues - MSN
Esperion Therapeutics: Q2 Earnings Snapshot - New Haven Register
What institutional flow reveals about Esperion Therapeutics Inc.Long-Term Stock Growth Forecast Insights - Newser
Esperion Therapeutics Inc (ESPR) Q2 2025 Earnings Call Highlights: Strong US Net Product ... By GuruFocus - Investing.com Canada
Esperion Therapeutics Reports Strong Q2 2025 Growth - TipRanks
Esperion Therapeutics Inc (ESPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Esperion Therapeutics Inc 주식 (ESPR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Halladay Benjamin | Chief Financial Officer |
Jul 17 '25 |
Sale |
1.11 |
11 |
12 |
474,462 |
2.37%
0.37%
자본화:
|
볼륨(24시간):